Index RUT
P/E -
EPS (ttm) -1.93
Insider Own 32.58%
Shs Outstand 87.23M
Perf Week 3.88%
Market Cap 1.25B
Forward P/E -
EPS next Y -1.81
Insider Trans -1.02%
Shs Float 59.16M
Perf Month 11.64%
Income -167.48M
PEG -
EPS next Q -0.62
Inst Own 73.46%
Short Float 22.94%
Perf Quarter 10.25%
Sales 8.19M
P/S 152.16
EPS this Y 17.67%
Inst Trans 2.04%
Short Ratio 13.79
Perf Half Y -8.51%
Book/sh 3.50
P/B 4.06
EPS next Y 7.11%
ROA -39.35%
Short Interest 13.57M
Perf Year 0.42%
Cash/sh 4.12
P/C 3.44
EPS next 5Y -
ROE -45.71%
52W Range 9.67 - 18.07
Perf YTD -2.74%
Dividend Est. -
P/FCF -
EPS past 5Y -84.59%
ROI -54.60%
52W High -21.42%
Beta -1.51
Dividend TTM -
Quick Ratio 4.09
Sales past 5Y 0.00%
Gross Margin 87.49%
52W Low 46.85%
ATR (14) 0.68
Dividend Ex-Date -
Current Ratio 4.09
EPS Y/Y TTM 15.21%
Oper. Margin -3570.91%
RSI (14) 51.91
Volatility 5.25% 4.33%
Employees 155
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -2044.43%
Recom 1.27
Target Price 36.44
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 91.73%
Payout -
Rel Volume 0.47
Prev Close 14.50
Sales Surprise 698.21%
EPS Surprise 93.34%
Sales Q/Q -
Earnings Jul 30 BMO
Avg Volume 984.01K
Price 14.20
SMA20 2.61%
SMA50 -0.59%
SMA200 -1.62%
Trades
Volume 465,758
Change -2.07%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-01-24 Upgrade
BofA Securities
Underperform → Buy
$11 → $24
Apr-24-24 Reiterated
Needham
Buy
$30 → $33
Apr-25-23 Downgrade
BofA Securities
Buy → Underperform
$34 → $9
Feb-08-23 Initiated
CapitalOne
Overweight
$40
Feb-03-23 Initiated
Oppenheimer
Perform
Dec-15-22 Initiated
H.C. Wainwright
Buy
$35
Dec-14-22 Initiated
Needham
Buy
$40
Dec-05-22 Initiated
Goldman
Buy
$45
Dec-01-22 Initiated
BofA Securities
Buy
$34
Aug-27-24 12:49PM
Aug-19-24 11:15AM
Aug-14-24 11:46AM
Jul-30-24 01:52PM
08:40AM
07:30AM
Loading…
07:30AM
07:00AM
Jul-25-24 11:53AM
(Pharmaceutical Technology)
12:58AM
Jun-27-24 09:51AM
Jun-24-24 04:50PM
Jun-22-24 04:11AM
Jun-19-24 12:14PM
(Pharmaceutical Technology)
10:29AM
Jun-18-24 08:30AM
07:46AM
Loading…
Jun-11-24 07:46AM
May-30-24 08:30AM
May-07-24 09:25AM
May-06-24 10:53PM
04:30PM
03:22AM
May-04-24 02:31AM
Apr-23-24 03:56PM
03:54PM
Mar-13-24 07:07AM
Feb-28-24 04:32AM
Feb-26-24 04:30PM
Jan-31-24 05:12PM
Jan-17-24 08:00AM
Dec-19-23 08:00AM
10:00AM
Loading…
Nov-27-23 10:00AM
Nov-17-23 07:00AM
Nov-14-23 08:00AM
Nov-06-23 05:16PM
04:30PM
Nov-04-23 12:16PM
Oct-30-23 07:27PM
08:00AM
Oct-23-23 01:20PM
Oct-20-23 10:20AM
Sep-29-23 12:43PM
Sep-11-23 09:02PM
Aug-16-23 08:00AM
Aug-10-23 02:28PM
Aug-07-23 04:30PM
Jun-17-23 08:29AM
Jun-12-23 08:00AM
Jun-08-23 12:38PM
07:00AM
Jun-06-23 10:31PM
04:01PM
Jun-05-23 04:06PM
(Investor's Business Daily)
12:30PM
Jun-04-23 12:45PM
May-30-23 08:00AM
May-25-23 08:30PM
05:00PM
May-01-23 09:00AM
Apr-30-23 09:57AM
Apr-26-23 09:31AM
Apr-21-23 01:02PM
11:44AM
Apr-12-23 08:00AM
Mar-21-23 05:30AM
(South China Morning Post)
Mar-06-23 04:30PM
Feb-27-23 08:00AM
Feb-15-23 10:24AM
Jan-09-23 08:57AM
08:30AM
Jan-08-23 05:00PM
Jan-03-23 01:04AM
01:00AM
Dec-20-22 08:00AM
Dec-14-22 01:02PM
Dec-05-22 09:05AM
Nov-21-22 08:33AM
Nov-17-22 07:00AM
Nov-11-22 07:00AM
Nov-07-22 04:30PM
Oct-17-22 08:00AM
Sep-12-22 08:30AM
Aug-09-22 08:50AM
Aug-04-22 04:30PM
(GlobeNewswire) +6.90%
+15.60%
Aug-02-22 08:00AM
Jul-29-22 11:33AM
Jul-18-22 09:55AM
Jun-30-22 01:08PM
Jun-23-22 07:26PM
Jun-21-22 08:30AM
Jun-15-22 02:45PM
(Investor's Business Daily)
05:41AM
Jun-14-22 08:00PM
05:42PM
05:34PM
(American City Business Journals)
09:05AM
07:30AM
Jun-13-22 04:17PM
(Investor's Business Daily) +125.98%
07:56AM
Jun-12-22 05:00PM
May-23-22 08:30AM
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dubow Adam GENERAL COUNSEL Aug 16 '24 Sale 14.00 3,202 44,825 26,928 Aug 19 06:12 PM York Charles N II COO, CFO AND SECRETARY Aug 16 '24 Sale 14.00 2,633 36,860 232,485 Aug 19 06:07 PM Blackman Samuel C. HEAD OF R&D Aug 16 '24 Sale 14.00 2,232 31,246 1,127,535 Aug 19 05:59 PM Bender Jeremy CHIEF EXECUTIVE OFFICER Aug 16 '24 Sale 14.00 10,681 149,524 98,932 Aug 19 05:53 PM JEREMY BENDER Officer Aug 16 '24 Proposed Sale 14.00 10,681 149,524 Aug 16 05:23 PM SAMUEL BLACKMAN Officer Aug 16 '24 Proposed Sale 14.00 2,232 31,246 Aug 16 05:17 PM Blackman Samuel C. HEAD OF R&D Jul 16 '24 Sale 16.01 20,000 320,226 1,121,081 Jul 17 04:53 PM Ramasastry Saira Director Jun 21 '24 Sale 13.19 10,000 131,877 40,485 Jun 21 07:17 PM Blackman Samuel C. HEAD OF R&D Jun 10 '24 Sale 12.62 30,000 378,588 1,141,081 Jun 12 04:29 PM Bender Jeremy CHIEF EXECUTIVE OFFICER May 16 '24 Sale 16.08 7,873 126,588 654,728 May 17 06:27 PM Blackman Samuel C. HEAD OF R&D May 16 '24 Sale 16.08 2,267 36,450 1,171,081 May 17 06:18 PM York Charles N II COO, CFO AND SECRETARY May 16 '24 Sale 16.08 2,675 43,011 224,868 May 17 06:15 PM Dubow Adam GENERAL COUNSEL May 16 '24 Sale 16.08 3,253 52,304 21,731 May 17 06:11 PM Blackman Samuel C. HEAD OF R&D May 10 '24 Sale 16.37 10,000 163,743 1,164,662 May 14 06:13 PM Bender Jeremy CHIEF EXECUTIVE OFFICER May 01 '24 Sale 17.88 70,051 1,252,183 651,762 May 03 06:48 PM Bender Jeremy CHIEF EXECUTIVE OFFICER May 03 '24 Sale 17.85 9,154 163,417 642,602 May 03 06:48 PM Bender Jeremy CHIEF EXECUTIVE OFFICER May 02 '24 Sale 17.94 6 108 651,756 May 03 06:48 PM York Charles N II COO, CFO AND SECRETARY May 01 '24 Sale 17.89 52,183 933,397 225,571 May 03 06:44 PM York Charles N II COO, CFO AND SECRETARY May 03 '24 Sale 17.85 8,078 144,214 217,293 May 03 06:44 PM York Charles N II COO, CFO AND SECRETARY May 02 '24 Sale 17.90 200 3,579 225,371 May 03 06:44 PM Blackman Samuel C. HEAD OF R&D Apr 18 '24 Sale 16.02 10,000 160,163 1,174,662 Apr 22 06:36 PM Blackman Samuel C. HEAD OF R&D Mar 25 '24 Sale 16.01 10,000 160,055 1,184,662 Mar 26 06:09 PM Blackman Samuel C. HEAD OF R&D Mar 11 '24 Sale 15.24 30,000 457,314 1,194,662 Mar 13 04:24 PM Blackman Samuel C. HEAD OF R&D Feb 27 '24 Sale 16.11 20,000 322,166 1,224,662 Feb 28 07:55 PM Dubow Adam GENERAL COUNSEL Feb 16 '24 Sale 15.25 3,242 49,434 16,585 Feb 20 06:48 PM York Charles N II COO, CFO AND SECRETARY Feb 16 '24 Sale 15.25 2,666 40,651 277,754 Feb 20 06:36 PM Blackman Samuel C. HEAD OF RESEARCH AND DEVELOPME Feb 16 '24 Sale 15.25 2,258 34,430 1,244,662 Feb 20 06:26 PM Bender Jeremy CHIEF EXECUTIVE OFFICER Feb 16 '24 Sale 15.25 7,615 116,114 721,813 Feb 20 06:14 PM York Charles N II COO, CFO and Secretary Nov 16 '23 Sale 11.69 956 11,176 270,170 Nov 17 06:33 PM Dubow Adam General Counsel Nov 16 '23 Sale 11.69 5,313 62,109 11,428 Nov 17 06:30 PM Blackman Samuel C. Head of Research and Developme Nov 16 '23 Sale 11.69 709 8,288 1,238,234 Nov 17 06:26 PM Bender Jeremy Chief Executive Officer Nov 16 '23 Sale 11.69 3,107 36,321 709,429 Nov 17 06:20 PM AI Day1 LLC 10% Owner Oct 18 '23 Buy 10.21 979,667 10,000,049 12,433,535 Oct 20 04:02 PM AI Day1 LLC 10% Owner Oct 19 '23 Buy 10.06 384,400 3,867,372 12,817,935 Oct 20 04:02 PM AI Day1 LLC 10% Owner Oct 20 '23 Buy 9.97 111,387 1,110,907 12,929,322 Oct 20 04:02 PM
Index RUT
P/E -
EPS (ttm) -3.58
Insider Own 35.64%
Shs Outstand 134.78M
Perf Week -6.51%
Market Cap 1.06B
Forward P/E -
EPS next Y -3.77
Insider Trans -0.18%
Shs Float 87.95M
Perf Month -6.62%
Income -483.04M
PEG -
EPS next Q -1.05
Inst Own 51.03%
Short Float 6.40%
Perf Quarter -35.23%
Sales 78.88M
P/S 13.44
EPS this Y 26.24%
Inst Trans -5.27%
Short Ratio 5.47
Perf Half Y -31.08%
Book/sh 10.50
P/B 0.74
EPS next Y -11.34%
ROA -24.69%
Short Interest 5.63M
Perf Year -35.71%
Cash/sh 8.53
P/C 0.91
EPS next 5Y 7.00%
ROE -29.78%
52W Range 7.52 - 13.09
Perf YTD -22.86%
Dividend Est. -
P/FCF -
EPS past 5Y -34.12%
ROI -31.60%
52W High -40.72%
Beta 0.48
Dividend TTM -
Quick Ratio 12.51
Sales past 5Y 421.39%
Gross Margin 73.88%
52W Low 3.19%
ATR (14) 0.38
Dividend Ex-Date Nov 03, 2010
Current Ratio 12.51
EPS Y/Y TTM -83.41%
Oper. Margin -648.66%
RSI (14) 34.52
Volatility 3.93% 4.03%
Employees 587
Debt/Eq 0.08
Sales Y/Y TTM -83.93%
Profit Margin -612.40%
Recom 1.78
Target Price 31.25
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 30.09%
Payout -
Rel Volume 0.72
Prev Close 7.65
Sales Surprise -59.14%
EPS Surprise -13.97%
Sales Q/Q -19.02%
Earnings Aug 01 AMC
Avg Volume 1.03M
Price 7.76
SMA20 -7.70%
SMA50 -14.04%
SMA200 -19.71%
Trades
Volume 742,002
Change 1.44%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-29-24 Downgrade
JP Morgan
Overweight → Neutral
$23 → $9
Sep-08-23 Downgrade
BofA Securities
Buy → Neutral
$23 → $14
Mar-06-23 Upgrade
JP Morgan
Neutral → Overweight
$35 → $34
Feb-21-23 Upgrade
Goldman
Neutral → Buy
$41 → $53
Jan-27-23 Upgrade
Morgan Stanley
Underweight → Equal-Weight
$18 → $30
Sep-14-22 Initiated
SVB Leerink
Outperform
$40
Sep-09-22 Initiated
Morgan Stanley
Underweight
$15
Mar-03-22 Upgrade
Robert W. Baird
Underperform → Neutral
$36 → $28
Dec-21-21 Downgrade
Robert W. Baird
Neutral → Underperform
$36
Oct-25-21 Upgrade
JP Morgan
Underweight → Neutral
$29 → $37
Sep-22-21 Downgrade
Goldman
Buy → Neutral
$64 → $62
Jun-04-21 Resumed
Robert W. Baird
Neutral
$45
Jan-27-21 Downgrade
JP Morgan
Neutral → Underweight
$30
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$100 → $125
Oct-05-20 Initiated
BofA Securities
Buy
$55
Sep-14-20 Upgrade
Goldman
Neutral → Buy
$48 → $54
Sep-11-20 Upgrade
JP Morgan
Underweight → Neutral
$29
Aug-20-20 Initiated
Needham
Buy
$62
Mar-19-20 Downgrade
JP Morgan
Neutral → Underweight
$26
Mar-13-20 Downgrade
Goldman
Buy → Neutral
Show Previous Ratings
Sep-04-24 08:30AM
Aug-22-24 08:05AM
Aug-06-24 09:55AM
Aug-01-24 05:50PM
04:02PM
04:01PM
Loading…
04:01PM
Jul-18-24 04:05PM
Jul-04-24 10:01AM
Jun-26-24 08:05AM
Jun-06-24 01:26PM
Jun-05-24 02:51PM
05:30AM
May-29-24 04:05PM
08:05AM
May-23-24 04:05PM
08:05AM
Loading…
May-22-24 08:05AM
May-21-24 08:17AM
May-13-24 07:21PM
May-09-24 10:46AM
May-07-24 09:55AM
May-03-24 01:05PM
06:05AM
(Thomson Reuters StreetEvents)
04:06AM
May-02-24 09:56PM
06:05PM
04:05PM
Apr-30-24 04:05PM
Apr-24-24 12:00PM
Apr-18-24 08:00AM
Apr-11-24 04:30PM
07:01PM
Loading…
Apr-04-24 07:01PM
Mar-22-24 07:00AM
Mar-19-24 02:58PM
Mar-13-24 11:07AM
Mar-05-24 08:05AM
Feb-23-24 01:54PM
(Thomson Reuters StreetEvents) +11.94%
10:34AM
09:55AM
08:05AM
Feb-22-24 05:50PM
04:05PM
Feb-20-24 04:30PM
Feb-14-24 03:45PM
Feb-01-24 04:05PM
Jan-15-24 11:32AM
Dec-17-23 07:00AM
07:00AM
Dec-13-23 04:05PM
Dec-06-23 04:05PM
Nov-30-23 06:10AM
Nov-13-23 08:00AM
Nov-10-23 08:00AM
Nov-08-23 08:05AM
Nov-04-23 11:42AM
Nov-03-23 09:02AM
(Thomson Reuters StreetEvents) +6.96%
Nov-02-23 07:00PM
04:05PM
Oct-30-23 08:00AM
Oct-23-23 02:50AM
Oct-12-23 04:05PM
Oct-11-23 08:00AM
Oct-05-23 04:30PM
Oct-03-23 07:59AM
Sep-20-23 08:00AM
Sep-19-23 05:07AM
Sep-08-23 09:34AM
Aug-29-23 04:30PM
Aug-12-23 11:05AM
Aug-11-23 10:15AM
Aug-07-23 06:03AM
Aug-04-23 01:40PM
Aug-03-23 06:05PM
04:05PM
Jul-26-23 04:05PM
Jul-21-23 10:11AM
Jul-20-23 04:50PM
(American City Business Journals) -44.90%
11:31AM
08:00AM
Jun-29-23 09:00AM
Jun-25-23 08:00AM
Jun-24-23 05:30AM
Jun-21-23 08:00PM
Jun-07-23 02:13AM
Jun-05-23 04:05PM
May-17-23 04:05PM
May-16-23 09:25AM
May-15-23 08:35AM
08:00AM
May-11-23 08:30AM
May-10-23 02:07PM
May-04-23 07:45PM
05:48PM
04:05PM
May-03-23 04:05PM
May-02-23 09:00AM
Apr-28-23 10:00AM
Apr-27-23 10:03AM
Apr-26-23 08:00PM
Apr-11-23 04:05PM
Apr-05-23 01:40PM
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ramasastry Saira Director Jun 11 '24 Sale 10.95 4,000 43,789 14,619 Jun 12 12:21 PM De Backer Marianne Chief Executive Officer Apr 03 '24 Sale 9.46 72,995 690,365 678,457 Apr 04 04:14 PM HANLY ANN M. EVP & Chief Technology Officer Apr 01 '24 Sale 10.05 2,711 27,251 132,069 Apr 02 08:58 PM Lee Sung EVP & Chief Financial Officer Mar 27 '24 Sale 9.89 6,008 59,404 100,492 Mar 28 12:18 PM HANLY ANN M. EVP & Chief Technology Officer Feb 22 '24 Sale 10.05 12,296 123,521 134,780 Feb 26 07:34 PM Pang Phillip EVP & Chief Medical Officer Feb 22 '24 Sale 10.05 14,568 146,344 250,111 Feb 26 07:31 PM SCANGOS GEORGE A Director Feb 26 '24 Sale 11.65 17,722 206,522 112,989 Feb 26 07:30 PM SCANGOS GEORGE A Director Feb 22 '24 Sale 10.05 10,028 100,737 130,711 Feb 26 07:30 PM SCANGOS GEORGE A Director Feb 20 '24 Sale 10.22 16,872 172,385 140,739 Feb 20 09:02 PM SCANGOS GEORGE A Director Feb 16 '24 Sale 10.24 10,878 111,386 157,611 Feb 20 09:02 PM Pang Phillip EVP & Chief Medical Officer Feb 16 '24 Sale 10.24 3,321 34,006 264,679 Feb 16 06:56 PM Pang Phillip EVP & Chief Medical Officer Jan 02 '24 Option Exercise 1.38 80,000 110,299 268,000 Jan 03 02:47 PM
Index RUT
P/E -
EPS (ttm) -2.34
Insider Own 20.68%
Shs Outstand 46.72M
Perf Week -2.05%
Market Cap 1.96B
Forward P/E -
EPS next Y -0.81
Insider Trans -0.45%
Shs Float 37.84M
Perf Month 5.54%
Income -106.65M
PEG -
EPS next Q -0.43
Inst Own 95.92%
Short Float 18.16%
Perf Quarter 64.74%
Sales 264.38M
P/S 7.42
EPS this Y 55.09%
Inst Trans 11.22%
Short Ratio 9.19
Perf Half Y 45.76%
Book/sh 4.81
P/B 8.54
EPS next Y 54.33%
ROA -19.32%
Short Interest 6.87M
Perf Year 44.23%
Cash/sh 5.83
P/C 7.05
EPS next 5Y -
ROE -69.35%
52W Range 23.14 - 45.23
Perf YTD 39.30%
Dividend Est. -
P/FCF -
EPS past 5Y -39.57%
ROI -19.59%
52W High -9.09%
Beta 1.16
Dividend TTM -
Quick Ratio 3.09
Sales past 5Y 88.90%
Gross Margin 73.04%
52W Low 77.70%
ATR (14) 1.90
Dividend Ex-Date -
Current Ratio 3.28
EPS Y/Y TTM 50.67%
Oper. Margin -40.07%
RSI (14) 50.25
Volatility 4.27% 4.77%
Employees 264
Debt/Eq 1.38
Sales Y/Y TTM 128.34%
Profit Margin -40.34%
Recom 1.09
Target Price 59.27
Option/Short Yes / Yes
LT Debt/Eq 1.38
EPS Q/Q 73.15%
Payout -
Rel Volume 0.29
Prev Close 41.65
Sales Surprise 3.79%
EPS Surprise -10.10%
Sales Q/Q 107.68%
Earnings Aug 07 AMC
Avg Volume 747.71K
Price 41.12
SMA20 -1.70%
SMA50 4.12%
SMA200 34.25%
Trades
Volume 218,908
Change -1.27%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-17-24 Initiated
Stifel
Buy
$48
Dec-18-23 Reiterated
H.C. Wainwright
Buy
$60 → $58
Nov-20-23 Resumed
JP Morgan
Overweight
$37
Nov-13-23 Initiated
Morgan Stanley
Overweight
$60
Oct-24-23 Initiated
Cantor Fitzgerald
Overweight
$50
Oct-17-23 Resumed
Evercore ISI
Outperform
$62
Sep-20-23 Initiated
JMP Securities
Mkt Outperform
$70
Sep-01-22 Initiated
Citigroup
Buy
$38
Sep-20-21 Initiated
JP Morgan
Overweight
$30
Aug-07-20 Upgrade
Raymond James
Outperform → Strong Buy
$28 → $48
Aug-03-20 Initiated
H.C. Wainwright
Buy
$52
Jul-31-20 Initiated
Piper Sandler
Overweight
$77
Jun-25-20 Initiated
Robert W. Baird
Outperform
$30
Aug-12-19 Initiated
ROTH Capital
Buy
$33
Aug-12-19 Initiated
Raymond James
Outperform
$28
Aug-12-19 Initiated
Guggenheim
Buy
$18
Aug-12-19 Initiated
Evercore ISI
Outperform
Aug-12-19 Initiated
Citigroup
Buy
$21
Show Previous Ratings
Sep-06-24 01:31PM
(Investor's Business Daily)
11:31AM
Aug-28-24 04:01PM
Aug-19-24 11:06AM
Aug-09-24 07:00PM
11:01AM
Loading…
Aug-08-24 11:01AM
Aug-07-24 05:25PM
04:01PM
Jul-31-24 04:30PM
Jul-29-24 07:28AM
Jul-25-24 08:30AM
Jul-12-24 01:22PM
(Investor's Business Daily)
Jul-10-24 07:00PM
Jul-09-24 10:37AM
Jul-08-24 11:38AM
08:30AM
Loading…
08:30AM
Jun-28-24 02:26PM
(Investor's Business Daily)
08:30AM
Jun-25-24 11:31AM
(Investor's Business Daily)
Jun-18-24 11:14AM
05:46AM
Jun-17-24 08:00AM
Jun-16-24 05:00PM
Jun-10-24 10:00PM
Jun-07-24 11:30AM
Jun-06-24 09:30AM
Jun-05-24 04:05PM
Jun-03-24 06:46AM
(Pharmaceutical Technology) +5.49%
May-31-24 08:30AM
May-29-24 08:30AM
10:02AM
Loading…
May-28-24 10:02AM
May-18-24 07:00AM
May-13-24 09:40AM
May-10-24 07:30PM
01:55PM
01:12PM
May-09-24 11:46AM
07:40AM
(Thomson Reuters StreetEvents)
03:49AM
May-08-24 04:02PM
May-07-24 04:10PM
11:29AM
08:30AM
May-02-24 02:33PM
May-01-24 04:10PM
Apr-25-24 10:02AM
Apr-10-24 09:30PM
Apr-02-24 08:30AM
Mar-29-24 11:30AM
Mar-25-24 11:46PM
07:00AM
Mar-15-24 09:32AM
Mar-13-24 06:00PM
Mar-08-24 07:30PM
Mar-05-24 08:00AM
Feb-29-24 11:34AM
09:49AM
08:30AM
Feb-28-24 05:35PM
04:38PM
04:03PM
Feb-21-24 04:05PM
Feb-09-24 09:15PM
Feb-05-24 07:00AM
Jan-23-24 11:44AM
Jan-19-24 09:30PM
Jan-16-24 08:30AM
Jan-15-24 04:03AM
Jan-10-24 07:00PM
Jan-08-24 08:30AM
Jan-03-24 08:45AM
Dec-18-23 01:05PM
(Associated Press Finance) -15.87%
08:37AM
08:30AM
Dec-08-23 07:30PM
Nov-30-23 09:45AM
Nov-20-23 04:05PM
Nov-13-23 02:00PM
Nov-10-23 05:30PM
Nov-06-23 09:10AM
Nov-03-23 08:30AM
Nov-02-23 07:13PM
04:05PM
Oct-30-23 10:00AM
08:30AM
Oct-27-23 08:45AM
Oct-17-23 04:30PM
Oct-11-23 04:52PM
Oct-10-23 08:00PM
Oct-07-23 05:00PM
Oct-02-23 08:30AM
Sep-26-23 08:30AM
Sep-21-23 08:30AM
Sep-15-23 03:05PM
08:30AM
06:01AM
Sep-14-23 01:15PM
Sep-13-23 01:01PM
Sep-11-23 10:07AM
Sep-08-23 11:30PM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Peetz Christopher CHIEF EXECUTIVE OFFICER Jul 23 '24 Option Exercise 2.94 34,013 99,862 126,783 Jul 24 05:32 PM Howe Jolanda SVP, GLOBAL CONTROLLER Jul 02 '24 Sale 34.00 375 12,750 2,426 Jul 03 06:19 PM Vig Pamela CHIEF SCIENTIFIC OFFICER Jun 24 '24 Option Exercise 2.94 30,559 89,721 57,965 Jun 25 05:15 PM Vig Pamela CHIEF SCIENTIFIC OFFICER Jun 24 '24 Sale 34.00 30,559 1,039,006 27,406 Jun 25 05:15 PM Ramasastry Saira Director Jun 05 '24 Option Exercise 14.12 5,000 70,600 5,000 Jun 07 06:20 PM Ramasastry Saira Director Jun 05 '24 Sale 25.68 5,000 128,400 0 Jun 07 06:20 PM BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Mar 27 '24 Buy 24.80 2,000 49,600 14,000 Mar 27 08:47 PM Radovich Peter PRESIDENT AND COO Mar 25 '24 Sale 25.80 4,303 111,017 29,013 Mar 25 05:41 PM BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Mar 18 '24 Buy 25.80 2,000 51,600 12,000 Mar 18 05:34 PM Vig Pamela CHIEF SCIENTIFIC OFFICER Feb 02 '24 Sale 26.19 1,214 31,797 28,691 Feb 05 09:12 PM Longpre Lara CHIEF DEVELOPMENT OFFICER Feb 02 '24 Sale 26.19 847 22,184 104,407 Feb 05 09:10 PM Radovich Peter PRESIDENT AND COO Feb 02 '24 Sale 26.19 1,790 46,883 34,695 Feb 05 09:05 PM Peetz Christopher CHIEF EXECUTIVE OFFICER Feb 02 '24 Sale 26.19 6,013 157,491 104,112 Feb 05 09:04 PM Howe Jolanda SVP, GLOBAL CONTROLLER Feb 02 '24 Sale 26.19 735 19,251 1,759 Feb 02 09:28 PM Radovich Peter CHIEF OPERATING OFFICER Jan 08 '24 Sale 28.03 1,408 39,473 36,485 Jan 09 08:28 PM Longpre Lara CHIEF DEVELOPMENT OFFICER Jan 08 '24 Sale 28.04 1,019 28,568 105,254 Jan 09 08:25 PM Vig Pamela HEAD OF RESEARCH & DEVELOPMENT Jan 08 '24 Sale 28.03 1,408 39,472 29,905 Jan 09 08:21 PM Peetz Christopher PRESIDENT AND CEO Jan 08 '24 Sale 28.03 5,209 146,033 110,125 Jan 09 08:12 PM Howe Jolanda SVP, GLOBAL CONTROLLER Jan 08 '24 Sale 28.04 528 14,803 722 Jan 09 08:09 PM Howe Jolanda SVP, Global Controller Dec 05 '23 Option Exercise 2.94 2,500 7,350 2,500 Dec 06 05:16 PM Howe Jolanda SVP, Global Controller Dec 05 '23 Sale 32.40 2,500 81,000 0 Dec 06 05:16 PM Heron Patrick J Director Sep 13 '23 Buy 31.02 2,625 81,425 159,053 Sep 15 04:56 PM GREY MICHAEL G Director Sep 14 '23 Option Exercise 2.94 14,216 41,738 14,216 Sep 14 07:33 PM GREY MICHAEL G Director Sep 13 '23 Option Exercise 2.94 392 1,151 392 Sep 14 07:33 PM GREY MICHAEL G Director Sep 14 '23 Sale 32.00 14,216 454,912 0 Sep 14 07:33 PM GREY MICHAEL G Director Sep 13 '23 Sale 32.00 392 12,544 0 Sep 14 07:33 PM Heron Patrick J Director Sep 11 '23 Buy 30.30 4,687 142,027 152,678 Sep 13 04:39 PM Heron Patrick J Director Sep 12 '23 Buy 30.60 3,750 114,764 156,428 Sep 13 04:39 PM BJERKHOLT ERIC Chief Financial Officer Sep 11 '23 Buy 29.65 10,000 296,492 10,000 Sep 12 06:23 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite